Why Guidelines Stopped Recommending Reliever-Only Asthma Treatment

For decades, the first inhaler most people with mild asthma received was a short-acting reliever such as albuterol, taken alone whenever wheeze or breathlessness appeared. In 2019 the Global Initiative for Asthma (GINA) stopped recommending that a short-acting reliever be used on its own, and it has held that position through its 2024 strategy report. The change rested on a run of large randomized trials showing that a reliever combining a low-dose inhaled corticosteroid with formoterol reduced severe asthma attacks by roughly 60 percent compared with a short-acting reliever used alone. Reliever-only treatment relaxed the airway muscle during a flare but left the underlying inflammation untouched, and that gap carried more risk than the older approach acknowledged.

The habit that lasted forty years

The reliever-first model made intuitive sense. Asthma symptoms come from airway narrowing, a short-acting beta-agonist (SABA) opens the airway within minutes, and for someone with occasional symptoms a single quick-acting inhaler seemed proportionate to the problem. Inhaled corticosteroids, the anti-inflammatory controllers, were reserved for people whose symptoms crossed a frequency threshold.

The weakness in that logic showed up in how patients actually behaved. Many people with mild asthma relied on the reliever alone for years, felt well between attacks, and never started a controller. Yet airway inflammation persisted quietly, and heavy reliance on a SABA was associated with more exacerbations and with asthma deaths. The GINA 2024 report is direct on this point: treatment with a short-acting reliever alone increases the risk of severe exacerbations and asthma-related death, and adding an inhaled corticosteroid lowers that risk. The reliever people trusted most was also a marker of the danger they were in.

What the SYGMA trials tested

The turning evidence came from two trials published together in the New England Journal of Medicine in 2018, SYGMA 1 and SYGMA 2, which between them enrolled more than 8,000 patients aged 12 and older with mild asthma. Both tested a reliever that pairs the corticosteroid budesonide with formoterol, a beta-agonist fast enough to relieve symptoms within minutes but longer-acting than albuterol.

SYGMA 1 compared as-needed budesonide-formoterol against an as-needed short-acting reliever. The risk of a severe exacerbation was 64 percent lower with the combination reliever. SYGMA 2 asked a harder question: could a reliever taken only when needed match a daily controller inhaler? It could. As-needed budesonide-formoterol was noninferior to twice-daily maintenance budesonide for preventing severe exacerbations, and it achieved that while delivering roughly a quarter of the inhaled steroid. That last detail mattered to clinicians who weigh cumulative steroid exposure in people with mild disease.

Open-label trials outside the research bubble

Placebo-controlled trials keep patients and investigators blinded and can enforce adherence in ways ordinary care does not. To see whether the effect survived real-world use, two open-label trials let patients manage their inhalers as they would at home.

Novel START, published in the New England Journal of Medicine in 2019, randomized adults with mild asthma to as-needed albuterol, as-needed budesonide-formoterol, or daily budesonide plus as-needed albuterol. Severe exacerbations were about 60 percent lower with the combination reliever than with albuterol alone (nine events versus twenty-three; relative risk 0.40), and the annual exacerbation rate was roughly halved. PRACTICAL, published in The Lancet the same year, went further and compared the as-needed combination reliever directly against a daily budesonide controller plus a short-acting reliever. Severe exacerbations were lower with the as-needed combination (relative rate 0.69), meaning a reliever used only during symptoms outperformed a standing daily controller in this population.

Why 60 percent settled the question

No single figure decides a guideline, but consistency does a great deal of work. Across a blinded efficacy trial and an open-label pragmatic trial, the same intervention cut severe attacks by close to 60 percent against reliever-only treatment, and it matched or beat daily controllers while exposing patients to less steroid. The mechanism explains the reproducibility. When a person with worsening asthma reaches for the inhaler, airway inflammation is usually rising at that same moment. A combination reliever delivers an anti-inflammatory dose precisely when symptoms signal trouble, so the treatment scales with the disease instead of ignoring it.

That reframing is what GINA adopted. From 2019 onward the strategy no longer endorsed a short-acting reliever as stand-alone therapy for adults and adolescents, and it positioned as-needed low-dose ICS-formoterol as the preferred reliever across mild disease, a stance carried into the 2024 report.

What the shift does and does not mean

A few boundaries keep this in proportion. The evidence applies to formoterol-containing relievers because formoterol acts within minutes; the finding does not transfer to slower long-acting beta-agonists, which are unsafe as sole relievers. Not every national body has aligned identically, and treatment for young children and for severe asthma follows separate logic. This article is educational and not medical advice, and any change to an asthma regimen belongs in a conversation with the clinician who knows the individual case.

The larger lesson is about how a comfortable default can outlive its evidence. Reliever-only asthma care was reasonable when airway narrowing was seen as the whole problem. Once trials measured what happened over a full year, the quiet inflammation that reliever-only treatment left behind became impossible to ignore.